PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT PART 03: RESEARCH METHODOLOGY PART 04: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 05: MARKET SIZING • Market definition • Market sizing 2017 • Market size and forecast 2017-2022 PART 06: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 07: MARKET SEGMENTATION BY PRODUCT • Segmentation by product • Comparison by product • Estrogen gels – Market size and forecast 2017-2022 • Oral medication – Market size and forecast 2017-2022 • Suppositories – Market size and forecast 2017-2022 • Skin patches – Market size and forecast 2017-2022 • Market opportunity by product PART 08: CUSTOMER LANDSCAPE PART 09: MARKET SEGMENTATION BY ESTROGEN TYPE • Estradiol • Estrone • Estetrol • Estriol PART 10: REGIONAL LANDSCAPE • Geographical segmentation • Regional comparison • Americas – Market size and forecast 2017-2022 • EMEA – Market size and forecast 2017-2022 • APAC – Market size and forecast 2017-2022 • Key leading countries • Market opportunity PART 11: DECISION FRAMEWORK PART 12: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 13: MARKET TRENDS • Evolution of estrogen as a therapeutic target in neurodevelopmental disorders • Development of innovative estrogen delivery systems • Increase in FDA approvals for new estrogen therapeutic products PART 14: VENDOR LANDSCAPE • Overview • Landscape disruption PART 15: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • Abbott • Bayer • Novartis • Novo Nordisk • Pfizer PART 16: APPENDIX • List of abbreviations Exhibit 01: Parent market Exhibit 02: Global HRT market Exhibit 03: Market characteristics Exhibit 04: Market segments Exhibit 05: Market definition - Inclusions and exclusions checklist Exhibit 07: Market size 2017 Exhibit 08: Validation techniques employed for market sizing 2017 Exhibit 09: Global – Market size and forecast 2017-2022 ($ mn) Exhibit 10: Global – Year-over-year growth 2018-2022 (%) Exhibit 11: Five forces analysis 2017 Exhibit 12: Five forces analysis 2022 Exhibit 13: Bargaining power of buyers Exhibit 14: Bargaining power of suppliers Exhibit 15: Threat of new entrants Exhibit 16: Threat of substitutes Exhibit 17: Threat of rivalry Exhibit 18: Market condition - Five forces 2017 Exhibit 19: Product – Market share 2017-2022 (%) Exhibit 20: Comparison by product Exhibit 21: Estrogen gels – Market size and forecast 2017-2022 ($ mn) Exhibit 22: Estrogen gels – Year-over-year growth 2018-2022 (%) Exhibit 23: Oral medication – Market size and forecast 2017-2022 ($ mn) Exhibit 24: Oral medication – Year-over-year growth 2018-2022 (%) Exhibit 25: Suppositories – Market size and forecast 2017-2022 ($ mn) Exhibit 26: Suppositories – Year-over-year growth 2018-2022 (%) Exhibit 27: Skin patches – Market size and forecast 2017-2022 ($ mn) Exhibit 28: Skin patches – Year-over-year growth 2018-2022 (%) Exhibit 29: Market opportunity by product Exhibit 30: Customer landscape Exhibit 31: Global – Market share by geography 2017-2022 (%) Exhibit 32: Regional comparison Exhibit 33: Americas – Market size and forecast 2017-2022 ($ mn) Exhibit 34: Americas – Year-over-year growth 2018-2022 (%) Exhibit 35: EMEA – Market size and forecast 2017-2022 ($ mn) Exhibit 36: EMEA – Year-over-year growth 2018-2022 (%) Exhibit 37: APAC – Market size and forecast 2017-2022 ($ mn) Exhibit 38: APAC – Year-over-year growth 2018-2022 (%) Exhibit 39: Key leading countries Exhibit 40: Market opportunity Exhibit 41: Vendor landscape Exhibit 42: Landscape disruption Exhibit 43: Vendors covered Exhibit 44: Vendor classification Exhibit 45: Market positioning of vendors Exhibit 46: Abbott - Vendor overview Exhibit 47: Abbott – Business segments Exhibit 48: Abbott – Organizational developments Exhibit 49: Abbott – Geographic focus Exhibit 50: Abbott – Segment focus Exhibit 51: Abbott – Key offerings Exhibit 52: Bayer - Vendor overview Exhibit 53: Bayer – Business segments Exhibit 54: Bayer – Organizational developments Exhibit 55: Bayer – Geographic focus Exhibit 56: Bayer – Segment focus Exhibit 57: Bayer – Key offerings Exhibit 58: Novartis - Vendor overview Exhibit 59: Novartis – Business segments Exhibit 60: Novartis – Organizational developments Exhibit 61: Novartis – Geographic focus Exhibit 62: Novartis – Segment focus Exhibit 63: Novartis – Key offerings Exhibit 64: Novo Nordisk - Vendor overview Exhibit 65: Novo Nordisk – Business segments Exhibit 66: Novo Nordisk – Organizational developments Exhibit 67: Novo Nordisk – Geographic focus Exhibit 68: Novo Nordisk – Segment focus Exhibit 69: Novo Nordisk – Key offerings Exhibit 70: Pfizer - Vendor overview Exhibit 71: Pfizer – Business segments Exhibit 72: Pfizer – Organizational developments Exhibit 73: Pfizer – Geographic focus Exhibit 74: Pfizer – Segment focus Exhibit 75: Pfizer – Key offerings  

Abbott Bayer Novartis Novo Nordisk Pfizer